Serial quantitative liver function tests in patients with primary biliary cirrhosis: a prospective long-term study

Area of Science:

• Hepatology
• Gastroenterology
• Internal Medicine

Background:

• Primary biliary cirrhosis (PBC) is a rare, chronic cholestatic liver disease with variable clinical progression.
• Ursodeoxycholic acid (UDCA) is an effective treatment for PBC, but its long-term impact on liver function requires further investigation.
• Assessing the utility of quantitative liver function tests in managing PBC patients undergoing UDCA therapy is crucial.

Purpose of the Study:

• To evaluate the long-term effects of UDCA therapy on conventional liver function tests in PBC patients.
• To determine the usefulness of serial quantitative liver function tests in the clinical management of PBC.
• To compare quantitative liver function test results between PBC patients and healthy volunteers.

Main Methods:

• A single-center, prospective, long-term study involving 15 PBC patients treated with UDCA (10 mg/kg b.w./day).
• Patients were followed for 4-5 years, with regular conventional liver function tests and annual quantitative tests (galactose elimination capacity, indocyanine green and lidocaine half-lives).
• Quantitative tests were also performed on healthy volunteers for comparison.

Main Results:

• UDCA therapy significantly improved conventional liver function tests, with effects sustained for 4-5 years.
• Quantitative liver function tests (GEC, ICG, lidocaine half-lives) did not differ significantly between PBC patients and healthy volunteers and remained stable in patients during UDCA therapy.
• Serial quantitative tests provided minimal additional information for therapy planning in this cohort, predominantly early-stage PBC patients.

Conclusions:

• UDCA therapy demonstrates sustained improvement in conventional liver function tests for PBC patients over 4-5 years.
• Quantitative liver function tests, including GEC, ICG, and lidocaine half-lives, appear to have limited added value in monitoring UDCA-treated early-stage PBC.
• Further research may be needed to identify specific roles for quantitative tests in advanced PBC or other cholestatic conditions.